Moderna Inc. stocks have been trading up by 143.43 percent amid strong optimism over its latest mRNA vaccine developments.
Click Here for a Millionaire's POV on Trading MRNA
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
Key Takeaways
- FDA approval of mFLUSIVA gives Moderna a fourth U.S. product and sets up a 2026–27 flu season launch, expanding its commercial respiratory franchise beyond COVID.
- Q2 2026 results showed modest revenue growth, a narrower net loss, and beats on both EPS and revenue, alongside tighter 2026 operating expense guidance and a better year‑end cash outlook.
- Management is targeting up to 10% 2026 revenue growth from 2025 levels, cutting FY26 cost‑of‑sales guidance to $1.7B and planning an even U.S./international revenue split.
- A failed Phase 3 norovirus study highlights pipeline risk, but pivotal 2026 readouts in oncology and rare disease keep multiple upside shots in play.
- Goldman Sachs and Citi raised their MRNA price targets while staying Neutral, signaling improving but still cautious Street expectations.
Live Update At 15:03:04 EDT: On Wednesday, August 19, 2026 Moderna Inc. stock [NASDAQ: MRNA] is trending up by 143.43%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
MRNA just went on a wild ride. The stock closed at $62.96 the prior day, then opened around $116 and ripped to an intraday high of $163.47 before settling near $153.27. That is a huge range and a clear momentum surge that active traders love to stalk.
Under the hood, Moderna is still losing money, but the direction is improving. Q2 2026 revenue was about $1.94B, with gross margin near 32.3%. The company posted a net loss of roughly $782M and negative free cash flow around $563M. That means MRNA is burning cash, but management tightened operating expense guidance and improved its year‑end cash outlook, backed by $5.14B in cash and short‑term investments and a solid current ratio of 2.3.
More Breaking News
- SMR Stock Holds Support As NuScale Builds Cash And Nuclear Deals
- TEM Stock Slides As Tempus AI Bets $1.5B On MRD
- MRVL Stock Jumps As New AI Memory Products Ignite Bullish Bets
- ZNB Stock Pulls Back As Traders Eye High-Volume Volatility
Margins are ugly on paper, with EBIT margin at roughly -138.7% and profit margins deeply negative. Yet traders are focused on trajectory, not just levels. The Q2 loss of $1.97 per share actually beat expectations, and shares initially rose more than 3% after the print. With low debt (total‑debt‑to‑equity about 0.18) and heavy R&D spend near $2.9B planned for 2026, MRNA is clearly prioritizing pipeline scale over near‑term profits, which fuels volatility but also future catalyst potential.
Why Traders Are Watching MRNA After mFLUSIVA Approval
The big story now is FDA approval of mFLUSIVA, Moderna’s mRNA‑1010 seasonal flu vaccine for adults 50+. This is the company’s fifth global product and fourth FDA‑approved shot, and it locks in a U.S. commercial launch for the 2026–27 flu season. For traders, that approval flips MRNA from a mostly COVID‑dependent name into a broader respiratory‑vaccine platform.
Regulators in Australia, Canada, and Europe are already reviewing mFLUSIVA, pointing to a global rollout if those decisions land in Moderna’s favor. That is exactly the kind of multi‑year revenue stream that can support a higher long‑term valuation, even if the stock still trades like a biotech swing vehicle in the near term.
Earnings added fuel to the story. MRNA beat Q2 EPS and revenue expectations, reported a narrower loss, and guided 2026 operating expenses lower, while reaffirming a target of up to 10% revenue growth from 2025 and trimming FY26 cost of sales to $1.7B from $1.8B. Management expects 2026 revenue to be split roughly 50/50 between U.S. and international markets, with 55% of second‑half 2026 revenue hitting in Q3, a critical detail for traders planning seasonal setups.
On the catalyst side, MRNA still has pivotal 2026 data coming for its intismeran cancer programs (including mRNA‑4157 with Merck) and rare disease projects, even after a key norovirus Phase 3 study failed to meet early success criteria. That mix of wins and setbacks is classic biotech: noisy, but full of tradable events. Wall Street is taking notice too—Citi lifted its target to $60 and Goldman to $67, both while staying Neutral—showing the Street is warming up without going all‑in.
Conclusion
MRNA’s chart now reflects a major shift in the story. The explosive move from the $60s into the $150s came as traders processed the mFLUSIVA approval, Q2 beats, and tighter guidance. The intraday tape shows multiple fast legs higher, hard pullbacks, and then more pushes—exactly the kind of liquidity and range that short‑term traders hunt.
At the same time, the fundamentals are still a tug‑of‑war. Moderna remains unprofitable, with negative operating cash flow and heavy R&D and capex commitments, but it sits on a sizable cash pile and low leverage. The growing list of approved products—now including a flu shot for adults 50+—helps de‑risk the long‑term model and may underpin MRNA on sharp pullbacks, especially as global flu and oncology catalysts stack up into 2026.
Traders should also keep an eye on the broader policy backdrop, including U.S. vaccine‑related executive orders that can swing sentiment across the whole vaccine complex, even when MRNA is not at the center. Add in new early‑stage work like the CEPI‑backed mRNA‑1469 Bundibugyo ebolavirus program, and the company’s optionality continues to widen.
For active traders, the message from the Sykes‑style playbook still applies here: “Patterns repeat, but you have to manage risk like every trade can go wrong,” as Tim Sykes often says. That mindset aligns closely with another core trading principle: As Tim Bohen, lead trainer with StocksToTrade says, “I focus on what a stock is doing, not what I want it to do. Let the stock prove itself before you make a move.”. MRNA now blends real products, a thick catalyst calendar, and big intraday ranges—prime territory for those who study the chart, respect the volatility, and use this information strictly for educational and research purposes, not as advice to trade.
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.